Pregnant women’s and policymakers’ preferences for the expansion of noninvasive prenatal screening: A discrete choice experiment approach study.20231130155206

Pregnant women’s and policymakers’ preferences for the expansion of noninvasive prenatal screening: A discrete choice experiment approach study.

Nguyen HM, Baradaran M, Daigle G, Nshimyumukiza L, Guertin JR, Reinharz D. Health Sci Rep. 2023;6(8):e1516. Published 2023 Aug 23. doi:10.1002/hsr2.1516. Open Access: Learn more

Tags: Patient Perspectives, Health Care Provider Perspectives, 2023, Canada, RAAs, CNVs

  • 272 pregnant women and 24 policymakers completed the questionnaire.
  • In the pregnant women group, all seven attributes were statistically significant, denoting their importance, with pregnant women placing the greatest importance on cost related to the test, followed by test performance, and degree of test result certainty.
  • In the policymakers group, three attributes were statistically significant: test performance, degree of test result certainty regarding the severity of the disability, and cost related to the test.
Health professionals and scientists’ views on genome-wide NIPT in the French public health system: Critical analysis of the ethical issues raised by prenatal genomics.20221130162106

Health professionals and scientists’ views on genome-wide NIPT in the French public health system: Critical analysis of the ethical issues raised by prenatal genomics.

Perrot A, Horn R. PLoS One. 2022;17(11):e0277010. Published 2022 Nov 1. doi:10.1371/journal.pone.0277010. Open Access: Learn more

Tags: Health Care Provider Perspectives, 2022, France, RAAs, CNVs

  • Qualitative semi-structured interviews with 17 health professionals between September 2021 and February 2022 and a comprehensive literature review.
  • “The results of our empirical research highlight the importance of addressing ethical issues related to the differing quality of counselling, the complexity of achieving informed consent, and the avoidance of harm to pregnant women in the feedback of findings beyond T21, T18 and T13. If there is an increase in the provision of GW-NIPT within the French public health system, it will be essential to promote medical practices that respect reproductive choices of women, support their autonomous decision and their understanding of the limitations and uncertainties associated with GW screening.”